Aeterna Zentaris Inc.
https://www.zentaris.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aeterna Zentaris Inc.
Curis And Autolus Rise On EHA Abstract Data
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
CDK4/6 Market: Is A Shakeup Underway?
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing